MetaVia (MTVA) Earnings Date & Reports

Key Takeaways

• MetaVia is expected to report third-quarter 2026 results in early-to-mid November, with consensus estimates pointing to a net loss per share in a range of roughly $0.73 to $0.94.
• As a clinical-stage biotech, MetaVia is not expected to report meaningful revenue, so investors will focus on operating expenses, cash runway, and program updates.
• The prior-year quarter produced a net loss of $1.54 per share, while the most recent quarter (Q2 2026) reported a loss of $0.90 per share, missing the consensus estimate of $0.82.
• Clinical momentum is building around DA-1726, the company's investigational GLP-1/glucagon dual agonist for obesity and MASH, following positive Phase 1 Part 3B interim data.
• Management has guided that 16-week topline data from the Phase 1 Part 3 study of DA-1726 is expected in the fourth quarter of 2026, making forward commentary a key focus.
• For additional context on this ticker, you can explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• You can also explore Trending AI Robots for AI-driven trading signals and market ideas.

Earnings Context and Why It Matters

MetaVia Inc. (MTVA) is a clinical-stage biotechnology company focused on cardiometabolic diseases, with no approved products and therefore no product revenue. For a pre-revenue biotech, the quarterly earnings release matters less for top-line figures and more for what it reveals about spending discipline, cash runway, and clinical execution. The company's lead asset, DA-1726, is an investigational once-weekly dual agonist targeting GLP-1 (glucagon-like peptide-1) and glucagon receptors for obesity and MASH (metabolic dysfunction-associated steatohepatitis). Recent interim Phase 1 data showing a 68% reduction in liver fat and a 13.5% placebo-adjusted weight loss have raised investor attention heading into the report.

Earnings Expectations

Analysts do not expect MetaVia to generate meaningful revenue this quarter, reflecting its clinical-stage status. Consensus estimates for third-quarter 2026 net loss per share range from approximately $0.73 to $0.94, depending on the data provider, compared with a net loss of $1.54 per share in the year-ago quarter. In the second quarter of 2026, MetaVia reported a loss of $0.90 per share, missing the consensus estimate of $0.82, with research and development expenses up 50% year over year to roughly $3.5 million, driven by the DA-1726 Phase 1 titration study. Investors will be watching for updates on the company's cash position, which stood near $12.6 million as of mid-2026, and on management's financing plans given an ongoing going-concern disclosure.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like MetaVia alongside broader biotech peers, the AI Screener can streamline the search for comparable setups and emerging signals.

Market Reaction and Investor Sentiment

MetaVia shares have been volatile, with a 52-week range spanning from roughly $0.97 to more than $14, reflecting the high-risk, high-reward profile of an early-stage biotech. Sentiment heading into this report has been shaped less by quarterly financials and more by clinical catalysts, particularly the positive DA-1726 interim data announced in early November. Key risk factors include the company's limited cash runway, the potential need for dilutive financing, and the inherent uncertainty of early-stage trial readouts. Historically, the stock has shown outsized moves around both earnings and data announcements, underscoring the elevated sensitivity to news flow.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter report, the most important near-term catalyst for MetaVia is the 16-week topline data from the Phase 1 Part 3 study of DA-1726, which management has guided for the fourth quarter of 2026. This readout could shape the program's next steps and influence the company's broader positioning in the competitive obesity and MASH landscape.

Investors should also monitor the company's cash position and any associated financing activity. With a reported cash balance near $12.6 million and ongoing research and development costs, management's ability to extend the runway without excessive shareholder dilution will be a central theme. A previously disclosed going-concern warning means funding strategy is likely to be a recurring focus of management commentary.

Finally, watch for updates on the lead asset's safety and tolerability profile, given that gastrointestinal side effects are a common concern across the GLP-1 class. Progress on vanoglipel (DA-1241), the company's GPR119 agonist for MASH and type 2 diabetes, also remains a secondary watch item. As always, early-stage clinical results carry substantial uncertainty, and outcomes may differ materially from interim observations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations